These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 34250995)

  • 1. An exosome-mimicking membrane hybrid nanoplatform for targeted treatment toward Kras-mutant pancreatic carcinoma.
    Deng L; Zhang H; Zhang Y; Luo S; Du Z; Lin Q; Zhang Z; Zhang L
    Biomater Sci; 2021 Aug; 9(16):5599-5611. PubMed ID: 34250995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of mutant KRAS and TP53 DNA in circulating exosomes from healthy individuals and patients with pancreatic cancer.
    Yang S; Che SP; Kurywchak P; Tavormina JL; Gansmo LB; Correa de Sampaio P; Tachezy M; Bockhorn M; Gebauer F; Haltom AR; Melo SA; LeBleu VS; Kalluri R
    Cancer Biol Ther; 2017 Mar; 18(3):158-165. PubMed ID: 28121262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the Oncogene KRAS Mutant Pancreatic Cancer by Synergistic Blocking of Lysosomal Acidification and Rapid Drug Release.
    Kong C; Li Y; Liu Z; Ye J; Wang Z; Zhang L; Kong W; Liu H; Liu C; Pang H; Hu Z; Gao J; Qian F
    ACS Nano; 2019 Apr; 13(4):4049-4063. PubMed ID: 30912923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KRAS-dependent cancer cells promote survival by producing exosomes enriched in Survivin.
    Chang WH; Nguyen TT; Hsu CH; Bryant KL; Kim HJ; Ying H; Erickson JW; Der CJ; Cerione RA; Antonyak MA
    Cancer Lett; 2021 Oct; 517():66-77. PubMed ID: 34111513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploiting macropinocytosis for drug delivery into KRAS mutant cancer.
    Liu H; Qian F
    Theranostics; 2022; 12(3):1321-1332. PubMed ID: 35154489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A recombinant chimeric protein specifically induces mutant KRAS degradation and potently inhibits pancreatic tumor growth.
    Pan T; Zhang Y; Zhou N; He X; Chen C; Liang L; Duan X; Lin Y; Wu K; Zhang H
    Oncotarget; 2016 Jul; 7(28):44299-44309. PubMed ID: 27322423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted nanodelivery of siRNA against KRAS G12D inhibits pancreatic cancer.
    Huang R; Du H; Cheng L; Zhang P; Meng F; Zhong Z
    Acta Biomater; 2023 Sep; 168():529-539. PubMed ID: 37451658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macropinocytic dextran facilitates KRAS-targeted delivery while reducing drug-induced tumor immunity depletion in pancreatic cancer.
    Yuan F; Sun M; Liu Z; Liu H; Kong W; Wang R; Qian F
    Theranostics; 2022; 12(3):1061-1073. PubMed ID: 35154474
    [No Abstract]   [Full Text] [Related]  

  • 9. A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.
    Zhao X; Wang X; Fang L; Lan C; Zheng X; Wang Y; Zhang Y; Han X; Liu S; Cheng K; Zhao Y; Shi J; Guo J; Hao J; Ren H; Nie G
    Cancer Lett; 2017 Aug; 402():61-70. PubMed ID: 28576749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer.
    Kamerkar S; LeBleu VS; Sugimoto H; Yang S; Ruivo CF; Melo SA; Lee JJ; Kalluri R
    Nature; 2017 Jun; 546(7659):498-503. PubMed ID: 28607485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors.
    Kazi A; Xiang S; Yang H; Chen L; Kennedy P; Ayaz M; Fletcher S; Cummings C; Lawrence HR; Beato F; Kang Y; Kim MP; Delitto A; Underwood PW; Fleming JB; Trevino JG; Hamilton AD; Sebti SM
    Clin Cancer Res; 2019 Oct; 25(19):5984-5996. PubMed ID: 31227505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exosome-mediated delivery of CRISPR/Cas9 for targeting of oncogenic Kras
    McAndrews KM; Xiao F; Chronopoulos A; LeBleu VS; Kugeratski FG; Kalluri R
    Life Sci Alliance; 2021 Sep; 4(9):. PubMed ID: 34282051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation and testing of clinical-grade exosomes for pancreatic cancer.
    Mendt M; Kamerkar S; Sugimoto H; McAndrews KM; Wu CC; Gagea M; Yang S; Blanko EVR; Peng Q; Ma X; Marszalek JR; Maitra A; Yee C; Rezvani K; Shpall E; LeBleu VS; Kalluri R
    JCI Insight; 2018 Apr; 3(8):. PubMed ID: 29669940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A CRISPR-Cas13a system for efficient and specific therapeutic targeting of mutant KRAS for pancreatic cancer treatment.
    Zhao X; Liu L; Lang J; Cheng K; Wang Y; Li X; Shi J; Wang Y; Nie G
    Cancer Lett; 2018 Sep; 431():171-181. PubMed ID: 29870774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aphanin, a triterpenoid from Amoora rohituka inhibits K-Ras mutant activity and STAT3 in pancreatic carcinoma cells.
    Rabi T; Catapano CV
    Tumour Biol; 2016 Sep; 37(9):12455-12464. PubMed ID: 27333990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kirsten Rat Sarcoma Viral Oncogene Homologue (KRAS) Mutations in the Occurrence and Treatment of Pancreatic Cancer.
    Zhu Z; Xiao S; Hao H; Hou Q; Fu X
    Curr Top Med Chem; 2019; 19(23):2176-2186. PubMed ID: 31456520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A recombinantly tailored β-defensin that displays intensive macropinocytosis-mediated uptake exerting potent efficacy against K-Ras mutant pancreatic cancer.
    Du Y; Shang BY; Sheng WJ; Zhang SH; Li Y; Miao QF; Zhen YS
    Oncotarget; 2016 Sep; 7(36):58418-58434. PubMed ID: 27517152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KRAS
    Hobbs GA; Der CJ
    Subcell Biochem; 2022; 98():205-221. PubMed ID: 35378710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phellodendrine chloride suppresses proliferation of KRAS mutated pancreatic cancer cells through inhibition of nutrients uptake via macropinocytosis.
    Thu PM; Zheng ZG; Zhou YP; Wang YY; Zhang X; Jing D; Cheng HM; Li J; Li P; Xu X
    Eur J Pharmacol; 2019 May; 850():23-34. PubMed ID: 30716311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRAS-enhanced macropinocytosis and reduced FcRn-mediated recycling sensitize pancreatic cancer to albumin-conjugated drugs.
    Liu H; Sun M; Liu Z; Kong C; Kong W; Ye J; Gong J; Huang DCS; Qian F
    J Control Release; 2019 Feb; 296():40-53. PubMed ID: 30653981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.